Afficher la notice abrégée

Overview of the current use of levosimendan in France: a prospective observational cohort study

dc.rights.licenseopenen_US
dc.contributor.authorCHOLLEY, Bernard
dc.contributor.authorBOJAN, Mirela
dc.contributor.authorGUILLON, Benoit
dc.contributor.authorBESNIER, Emmanuel
dc.contributor.authorMATTEI, Mathieu
dc.contributor.authorLEVY, Bruno
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorTAFER, Nadir
dc.contributor.authorDELMAS, Clément
dc.contributor.authorTONON, David
dc.contributor.authorROZEC, Bertrand
dc.contributor.authorFELLAHI, Jean-Luc
dc.contributor.authorLIM, Pascal
dc.contributor.authorLABASTE, François
hal.structure.identifierPhysiologie & médecine expérimentale du Cœur et des Muscles [U 1046] [PhyMedExp]
hal.structure.identifierCentre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
dc.contributor.authorROUBILLE, François
dc.contributor.authorCARUBA, Thibaut
dc.contributor.authorMAURIAT, Philippe
dc.contributor.authorBARBOT, Olivier
dc.contributor.authorLAURENT, Berthomieu
dc.contributor.authorBESSELAT, Anne-Marie
dc.contributor.authorKATRIEN, Blanchart
dc.contributor.authorBOUGLE, Adrien
dc.contributor.authorBOURGOIN, Pierre
dc.contributor.authorARNAUD, Causeret
dc.contributor.authorCHARBONNEAU, Hélène
dc.contributor.authorCRISTINAR, Mircea
dc.contributor.authorDESEBBE, Olivier
dc.contributor.authorELJEZI, Veldat
dc.contributor.authorGENET, Thibaud
dc.contributor.authorGRENIER, Maxime
dc.contributor.authorGUINOT, Pierre Grégoire
dc.contributor.authorLEBEL, Stéphane
dc.contributor.authorLEVY, Yael
dc.contributor.authorLION, François
dc.contributor.authorMANSOURATI, Jacques
dc.contributor.authorMARLIÈRE, Stéphanie
dc.contributor.authorMARTIN, Anne-Céline
dc.contributor.authorMEBAZAA, Alexandre
dc.contributor.authorMOHAMMAD, Usman
dc.contributor.authorMONSEGU, Jacques
dc.contributor.authorNESSLER, Nicolas
dc.contributor.authorORSEL, Isabelle
dc.contributor.authorPUYMIRAT, Etienne
dc.contributor.authorRECHER, Morgan
dc.contributor.authorSOUSSI, Sabri
dc.contributor.authorTROUSSARD, Vincent
dc.contributor.authorUHRY, Sabrina
dc.contributor.authorZIRPHILE, Xavier
dc.date.accessioned2023-10-09T14:59:52Z
dc.date.available2023-10-09T14:59:52Z
dc.date.issued2023-12
dc.identifier.issn2110-5820en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184368
dc.description.abstractEnAbstract Background Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale. Method The France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year. Results The patients included ( n = 602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock ( n = 250, 41.5%), decompensated heart failure ( n = 127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment ( n = 86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation ( n = 82, 13.6%). They received 0.18 ± 0.07 µg/kg/min levosimendan over 26 ± 8 h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up. Conclusions We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectArticle clinique
dc.title.enOverview of the current use of levosimendan in France: a prospective observational cohort study
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s13613-023-01164-3en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
bordeaux.journalAnnals of Intensive Careen_US
bordeaux.page69en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04179341
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcehal
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Annals%20of%20Intensive%20Care&rft.date=2023-12&rft.volume=13&rft.issue=1&rft.spage=69&rft.epage=69&rft.eissn=2110-5820&rft.issn=2110-5820&rft.au=CHOLLEY,%20Bernard&BOJAN,%20Mirela&GUILLON,%20Benoit&BESNIER,%20Emmanuel&MATTEI,%20Mathieu&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BMC_Annals_of Intensive_Care_2 ...
Taille:
1.316Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée